Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation

Table 3 Summary of the meta-analyses

Endpoint	RCTs before 2012 (1974–2012)		RCTs after 2012 (2013–2017)		Subgroup analysis	Total RCTs
Endpoint	HR/OR (95% CI)	p value	HR/OR (95% CI)	p value	p value	HR/OR (95% CI)	p value
OS	0.98 (0.91–1.06)	0.59	0.92 (0.76–1.11)	0.39	0.55	0.97 (0.90–1.04)	0.38
PFS	1.04 (0.94–1.14)	0.47	0.96 (0.75–1.22)	0.74	0.56	1.02 (0.91–1.13)	0.74
RR	1.16 (0.86–1.58)	0.33	1.00 (0.58–1.74)	1.00	0.64	1.11 (0.85–1.46)	0.45
1-year OS	0.90 (0.78–1.04)	0.15	0.85 (0.65–1.12)	0.25	0.72	0.88 (0.79–0.99)	0.03
2-year OS	0.85 (0.71–1.02)	0.09	0.90 (0.65–1.25)	0.53	0.78	0.87 (0.73–1.03)	0.11
3-month PFS	1.18 (0.90–1.54)	0.23	0.99 (0.56–1.75)	0.98	0.59	1.11 (0.85–1.46)	0.43
6-month PFS	1.02 (0.81–1.28)	0.86	0.78 (0.50–1.21)	0.26	0.29	0.91 (0.73–1.15)	0.44
1-year PFS	0.90 (0.74–1.09)	0.27	0.94 (0.54–1.61)	0.81	0.88	0.88 (0.69–1.13)	0.33
2-year PFS	0.89 (0.67–1.19)	0.43	0.90 (0.63–1.30)	0.59	0.95	0.90 (0.71–1.12)	0.34

Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial; RR, response rate

ISSN: 1471-2407